Back

Cardiovascular risk management in the era of SGLT2is

1 September 2019 (18:25 - 18:45)
Organised by:
Congress Presentation Part of: Rewriting the textbooks: SGLT2 inhibitors and cardiovascular disease in type 2 diabetes Cardiovascular Disease in Specific Populations ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Martin Cowie

London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Welcome and objectives.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
Heart failure with and without chronic kidney disease in type 2 diabetes
Professor O. Schnell (Munich, DE)
Slides Video
Presentation thumbnail
Interactive panel discussion
Professor F. Cosentino (Stockholm, SE) Professor M. Cowie (London, GB) Professor O. Schnell (Munich, DE)
Slides Video

Access the full session

Session thumbnail
Rewriting the textbooks: SGLT2 inhibitors and cardiovascular disease in type 2 diabetes

The Event

Event poster

ESC Congress 2019

1 September 2019 18:25 CET
You may be interested in
thumbnail
Congress Session
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the outpatient setting
27 August 2023
thumbnail
Webinar
Managing cardiovascular aspects in diabetes and metabolic syndrome patients
14 February 2022
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
27 August 2022
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources